Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2024 02:50 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition säkrar SEK 23,8 miljoner för den fortsatta kliniska utvecklingen av golexanolon

STOCKHOLM, SVERIGE, 19 december 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har genomfört en kapitalanskaffning om SEK 23,8 miljoner genom...
December 19, 2024 02:50 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone

STOCKHOLM, SWEDEN – December 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised SEK 23.8 million through a...
December 18, 2024 10:30 ET | Source: Karolinska Development AB (publ)

Karolinska Developments styrelse utser Ben Toogood till ny ordförande

STOCKHOLM, 18 december 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att bolagets styrelse utsett ledamoten Ben Toogood till ny styrelseordförande fram till nästa bolagsstämma. ...
December 18, 2024 10:30 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s Board of Directors appoints Ben Toogood as new Chairman

STOCKHOLM, SWEDEN – December 18, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company’s Board of Directors has appointed Ben Toogood as new Chairman until the next...
December 11, 2024 05:45 ET | Source: Karolinska Development AB (publ)

Karolinska Developments styrelseordförande avgår på egen begäran

STOCKHOLM, 11 december 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att bolagets styrelseordförande, professor Hans Wigzell, idag lämnar sin position på egen begäran. Styrelsen...
December 11, 2024 05:45 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s Chairman of the Board resigns at his own request

STOCKHOLM, SWEDEN – December 11, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company’s Chairman of the Board, Professor Hans Wigzell, has decided to resign from...
December 10, 2024 15:54 ET | Source: Karolinska Development AB (publ)

Karolinska Development avyttrar 4,6 miljoner aktier i portföljbolaget OssDsign

STOCKHOLM, SVERIGE 10 december 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) avyttrar 4,6 miljoner aktier i portföljbolaget OssDsign och stärker därmed investmentbolagets likviditet. Efter...
December 10, 2024 15:54 ET | Source: Karolinska Development AB (publ)

Karolinska Development divests 4,6 million shares in portfolio company OssDsign

STOCKHOLM, SWEDEN, December 10, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests 4,6 million shares in the portfolio company OssDsign and thereby strengthens the investment company’s...
December 09, 2024 08:03 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics initierar en fas 2-studie med sevuparin för behandling av kronisk njursjukdom med anemi

STOCKHOLM, SVERIGE, 9 december 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har doserat den första patienten i en klinisk fas 2-studie...
December 09, 2024 08:03 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia

STOCKHOLM, SWEDEN – December 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in a phase 2...